United Therapeutics Corporation (UTHR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

United Therapeutics Corporation (UTHR) Healthcare & Pipeline Overview

United Therapeutics Corporation develops and commercializes therapies for unmet medical needs, particularly in pulmonary arterial hypertension (PAH). With a strong portfolio of treatments like Remodulin and Tyvaso, the company maintains a significant market presence, driven by continuous innovation and strategic collaborations within the biotechnology sector.

What Is the Investment Thesis for UTHR?

With a robust profit margin of 40.6% and a gross margin of 86.6%, the company demonstrates strong financial performance. Key value drivers include the continued growth of Tyvaso and Orenitram, as well as potential approvals for pipeline products like Tyvaso DPI. The company's strategic collaborations and focus on innovative delivery systems, such as the Remunity Pump, further enhance its growth prospects. However, investors should be aware of potential risks related to patent expirations and competition from other biotechnology firms, including BIIB: Biogen Inc. and INCY: Incyte Corporation. The company's P/E ratio of 16.67 reflects its current valuation relative to earnings.

Based on FMP financials and quantitative analysis

UTHR Key Highlights

Market capitalization of $21.4B, reflecting substantial investor confidence in United Therapeutics' market position and future growth potential.

• Profit margin of 40.6%, indicating strong profitability and efficient cost management within the biotechnology sector.
• Gross margin of 86.6%, highlighting the company's ability to maintain high revenue relative to the cost of goods sold.
• Beta of 0.75, suggesting lower volatility compared to the overall market, which may appeal to risk-averse investors.
• No dividend yield, as the company reinvests earnings into research and development to fuel future growth and innovation.

Who Are UTHR's Competitors?

UTHR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UTHR's Key Strengths?

Strong portfolio of PAH treatments with established market presence.

• Innovative drug delivery systems, such as the Remunity Pump.
• High profit and gross margins.
• Strategic collaborations and licensing agreements.

What Are UTHR's Weaknesses?

Reliance on a limited number of key products.

• Potential for patent expirations and generic competition.
• High research and development costs.
• Regulatory risks associated with drug development and approval.

What Could Drive UTHR Stock Higher?

Potential FDA approval of Tyvaso DPI for PAH and PH-ILD.

• Clinical trial results from the Tyvaso PERFECT and TETON studies in PH-COPD.
• Development and commercialization of the Remunity Pump for subcutaneous delivery of treprostinil.
• Advancement of the Aurora-GT gene therapy program for pulmonary vascular disease.

What Are the Key Risks for UTHR?

Insider selling — insiders were net sellers of roughly $32.4M recently.

• Patent expirations on key products, leading to generic competition.
• Clinical trial failures for pipeline products.
• Changes in healthcare regulations and reimbursement policies.
• Competition from other biotechnology companies developing PAH treatments.
• Regulatory risks associated with drug development and approval.

What Are the Growth Opportunities for UTHR?

• Expansion of Tyvaso Franchise: United Therapeutics has a significant opportunity to expand the Tyvaso franchise through new formulations like Tyvaso DPI and new indications such as PH-ILD and PH-COPD. The market for pulmonary hypertension treatments is projected to reach $8 billion by 2028, driven by increasing prevalence and improved diagnosis. Successful clinical trials and regulatory approvals for these new formulations and indications could significantly boost revenue and market share.
• Development of Remunity Pump: The Remunity Pump offers a more convenient and patient-friendly method for delivering treprostinil, potentially increasing adherence and improving patient outcomes. The market for drug delivery systems is estimated at $24 billion, with a growing demand for subcutaneous delivery options. The Remunity Pump could capture a significant share of this market by providing a more reliable and user-friendly alternative to existing infusion systems.
• Advancement of Gene Therapy Program (Aurora-GT): The Aurora-GT gene therapy program represents a long-term growth opportunity for United Therapeutics. Gene therapy for pulmonary vascular disease is an emerging field with the potential to address the underlying causes of PAH. While still in early stages, successful development and commercialization of Aurora-GT could position United Therapeutics as a leader in this innovative area, with a potential market size exceeding $1 billion.
• Strategic Collaborations and Licensing Agreements: United Therapeutics' collaborations with companies like DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. provide access to new technologies and product candidates. These collaborations can accelerate the development and commercialization of new therapies and expand the company's product portfolio. The market for collaborative drug development is growing, with pharmaceutical companies increasingly relying on partnerships to drive innovation and reduce risk.
• Geographic Expansion: United Therapeutics has the opportunity to expand its geographic presence beyond the United States and into international markets. The global market for PAH treatments is growing, particularly in emerging economies with increasing healthcare access. By expanding its sales and marketing efforts into new regions, United Therapeutics can tap into new revenue streams and diversify its business.

What Are UTHR's Competitive Advantages?

• Patented therapies provide market exclusivity and protect against generic competition.
• Specialized expertise in developing and commercializing PAH treatments.
• Established relationships with healthcare providers and patient advocacy groups.
• Strong brand recognition and reputation in the PAH market.
• Innovative drug delivery systems, such as the Remunity Pump, provide a competitive advantage.

What Does UTHR Do?

United Therapeutics Corporation, founded in 1996 and headquartered in Silver Spring, Maryland, is a biotechnology company dedicated to developing and commercializing innovative products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company's primary focus is on pulmonary arterial hypertension (PAH) and related conditions. Its commercial therapies include Remodulin, used to diminish symptoms associated with exercise in PAH patients; Tyvaso, an inhaled formulation of treprostinil, enhancing exercise ability in PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil, also for enhancing exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance exercise ability in PAH patients. United Therapeutics is also actively involved in developing new therapies and formulations, including Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight pump for subcutaneous delivery of treprostinil; RemoPro and Ralinepag for PAH treatment; Aurora-GT, a gene therapy product for rebuilding blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, evaluating Tyvaso in patients with PH-COPD. The company has established strategic licensing and collaboration agreements with companies like DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. to advance its product pipeline and delivery systems. United Therapeutics operates both in the United States and internationally, maintaining a strong commitment to improving the lives of patients with severe and chronic conditions.

What Products and Services Does UTHR Offer?

• Develop and commercialize therapies for chronic and life-threatening diseases.
• Focus on pulmonary arterial hypertension (PAH) and related conditions.
• Offer Remodulin to diminish symptoms associated with exercise in PAH patients.
• Provide Tyvaso, an inhaled formulation of treprostinil, to enhance exercise ability in PAH and PH-ILD patients.
• Offer Orenitram, a tablet dosage form of treprostinil, to enhance exercise capacity in PAH patients.
• Provide Unituxin, a monoclonal antibody for treating high-risk neuroblastoma.
• Offer Adcirca, an oral PDE-5 inhibitor to enhance exercise ability in PAH patients.
• Develop new therapies and formulations, including Tyvaso DPI and Remunity Pump.

How Does UTHR Make Money?

• Develop, manufacture, and commercialize pharmaceutical products.
• Generate revenue through the sale of prescription drugs.
• Invest in research and development to expand product pipeline.
• Establish strategic collaborations and licensing agreements to access new technologies and markets.

What Industry Does UTHR Operate In?

United Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and intense competition. The market for PAH treatments is expanding, driven by increasing prevalence and improved diagnostic rates. Key trends include the development of novel drug delivery systems and personalized medicine approaches. The company competes with other major players in the biotechnology sector, including BIIB: Biogen Inc. and INCY: Incyte Corporation, who are also developing therapies for chronic and life-threatening diseases. The biotechnology industry is expected to continue growing, driven by advancements in genomics, proteomics, and other areas of research.

Who Are UTHR's Key Customers?

• Patients with pulmonary arterial hypertension (PAH).
• Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• Patients with high-risk neuroblastoma.
• Hospitals and clinics that treat these conditions.
• Pharmacies that dispense prescription drugs.

Over the past six months, United Therapeutics Corporation insiders filed 100 SEC Form 4 transactions — 92 sales and 8 purchases. On net that is roughly 65K shares disposed (about $32.4M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: United Therapeutics Corporation

Revenue for United Therapeutics Corporation came in at $783.3M during Q2 FY2026. The company recorded net income of $333.0M, with diluted EPS of $7.27. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, UTHR averaged $6.97 in diluted EPS.

UTHR Valuation & Market Position

With a $21.4B market cap, United Therapeutics Corporation sits in the large-cap segment of the market. Analyst price targets span from $515.00 to $735.00, with a consensus of $643.75. At the current price of $503.86, that implies approximately 28% upside potential. Relative to its peer group, UTHR's quantitative score of 97/100 is above the peer average of 84/100.

Return on equity for United Therapeutics Corporation stands at 20.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.2%, showing how much profit it generates from its asset base. UTHR trades at a trailing price-to-earnings ratio of 16.67, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.2%, the inverse of the P/E and a quick read on earnings relative to price.

United Therapeutics Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 19.16 places it in the safe zone, indicating low near-term bankruptcy risk.

United Therapeutics Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.2% below estimates on average.

Company Profile

United Therapeutics Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Silver Spring, US. The company is led by CEO Martine A. Rothblatt. UTHR has traded publicly since 1999.

UTHR Financials

UTHR Latest News

UTHR Analyst Consensus

UTHR MoonshotScore

Latest United Therapeutics Corporation Analysis

What Investors Ask About United Therapeutics Corporation (UTHR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources